|
Powered by Cell Signaling Technology |
Site Information |
---|
TGtDkLMtGVIsPER SwissProt Entrez-Gene |
Blast this site against: NCBI SwissProt PDB |
Site Group ID: 2861408 |
In vivo Characterization | |
---|---|
Methods used to characterize site in vivo: | |
Disease tissue studied: | |
Relevant cell line - cell type - tissue: |
Upstream Regulation | |
---|---|
Putative in vivo kinases: | |
Kinases, in vitro: |
References | |
---|---|
Rikova K (2009) CST Curation Set: 7879; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info |
|
Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48
18691976 Curated Info |
|
Badouel C, et al. (2006) M-phase MELK activity is regulated by MPF and MAPK. Cell Cycle 5, 883-9
16628004 Curated Info |
|
Beullens M, et al. (2005) Substrate specificity and activity regulation of protein kinase MELK. J Biol Chem 280, 40003-11
16216881 Curated Info |